Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: Frederick Langford who wrote (20864)	10/8/2001 3:50:23 PM
From: Smart_Money	Respond to of 208838

This market is trading strange. Going up while war related going up. wild.

To: Frederick Langford who wrote (20864)	10/8/2001 4:01:03 PM
From: hotlinktuna	Respond to of 208838

Agree Fred...though not pure plays...like ARXX, ANON (down today) and BEAV...on weakness....tuna

To: Frederick Langford who wrote (20864)	10/8/2001 4:09:15 PM
From: wgh613	Read Replies (1) \| Respond to of 208838

CPHD up nicely today. This was the news from 8/13. Cepheid and ETG to Develop Biological-Agent Detection Systems for Military And Other Applications Cepheid to Provide DNA Testing Components for Automated Systems SUNNYVALE, Calif. and BALTIMORE, Aug 13, 2001 /PRNewswire via COMTEX/ -- Cepheid (Nasdaq: CPHD chart, msgs), a developer of integrated DNA testing systems, and Baltimore-based Environmental Technologies Group Inc. (ETG), a part of London-based Smiths Aerospace, today announced they have formed a collaboration to develop biological-agent detection systems for military and other domestic preparedness applications. Under the agreement, the companies will develop and design bio-detection systems based on Cepheid's proprietary technologies for the capture, purification, amplification and detection of DNA. Cepheid will provide sub-systems and sub-assemblies to ETG for integration into, and manufacture of, fully automated bio-detection systems that will range from hand-held units to stationary monitoring systems for use in a variety of military and civilian settings. Cepheid's I-CORE(R) and microfluidic technologies will be key components of the DNA detection systems that will be manufactured and marketed on a worldwide basis by ETG and its sister company Graseby Dynamics Limited under royalty-bearing licenses from Cepheid. Financial and other terms of the agreement were not disclosed. "We are excited to enter into this partnership with ETG, a premier player in the field of chemical and biological detection systems for the United States military and its allies," said Tom Gutshall, chairman and CEO of Cepheid. "ETG is the ideal partner to adapt Cepheid's versatile DNA testing technology to the bio-defense market, and together we are committed to developing systems that deliver faster, more sensitive results under any conditions." Rick Thomas, president of ETG said, "Cepheid's technology has already gained a wide acceptance among U.S. Department of Defense and other governmental agencies responsible for domestic preparedness and military bio-threat defense. We will use our knowledge of these markets to configure applicable systems around Cepheid's technology, saving development time with systems designed specifically for the military and civilian defense markets." ETG is a leading provider of full-service, advanced engineering technology for nuclear, biological, and chemical detection systems for government and other commercial applications. ETG is part of the Smiths Aerospace Detection & Protection Systems along with Graseby Dynamics Ltd in the UK and Barringer Technologies in Canada. Smiths Aerospace is the leading transatlantic aerospace equipment company, with half its 12,000 staff and $2 billion revenues in North America. The Company holds key positions in the supply chains of all major military and civil aircraft and engine manufacturers and are world-leaders in electronic systems, detection and protection systems, actuation systems and precision components. Cepheid, based in Sunnyvale, Calif., is developing versatile, miniaturized instruments that perform all the steps required to rapidly analyze genetic material found in complex biological samples-sample preparation, amplification, and detection. Integrating proprietary microfluidic and microelectronic technologies, it is commercializing products initially for DNA and RNA analysis in clinical diagnostics, life science research, industrial testing and pharmacogenomics. Cepheid and I-CORE are registered trademarks of Cepheid. Statements in this release regarding Cepheid's relationship with ETG, including those that may relate to revenue growth, trends in financial or operational performance, litigation, new product plans and business prospects are forward-looking statements. Actual results might differ materially from these statements due to risks and uncertainties, including the impact of competitive products and pricing, market acceptance of new products, market conditions and enforcement of intellectual property rights. A more detailed description of these risks and other risks applicable to Cepheid appears in Cepheid's reports filed with the U.S. Securities and Exchange Commission and available upon request from Cepheid. Cepheid disclaims any intent or obligation to update these forward-looking statements.